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Abstract
Background Kerbs von Lungren 6 antigen (KL-6) is expressed
on the surface of alveolar type II cells, and elevated plasma and
epithelial lining fluid levels of KL-6 have previously been shown
to correlate with the severity of disease and survival in acute
respiratory distress syndrome (ARDS). The relationship
between alveolar inflammation and KL-6 measurements has not
been ascertained. We hypothesized that the elevation of KL-6 in
ARDS is dependent upon the severity of neutrophilic
inflammation. Furthermore we were interested in the relationship
between significant alveolar infection and KL-6 levels.
Methods Plasma arterial samples were collected from ARDS
patients on day 1 and when possible on day 4 along with
bronchoalveolar lavage fluid (BALF) samples on the same day.
Bacterial growth in the BALF was determined by quantitative
cultures and was defined as significant at counts >1 × 104
colony-forming units.
Results Plasma KL-6 levels in ARDS patients were elevated
compared with at-risk control individuals (P = 0.014) and with
normal control individuals (P = 0.02). The plasma KL-6 level
correlated with the Murray Lung Injury Score (r = 0.68, P =
0.001) and with BALF KL-6 (r = 0.3260, P = 0.04). The BALF
KL-6 level was detectable in all ARDS cases and was lower on
both day 0 and day 4 in those who survived. BALF KL-6 also
correlated with the BALF myeloperoxidase activity (r = 0.363, P
= 0.027), with the BALF cell count per millilitre (r = 0.318, P =
0.038), with BALF epithelial-cell-derived neutrophil attractant
78; (r = 0.37, P = 0.016) and with BALF vascular endothelial
growth factor (r = 0.35, P = 0.024). The BALF KL-6 level of
ARDS patients with significant pathogenic bacterial growth was
similar compared with those without significant infection.
Conclusion KL-6 may represent a useful marker of alveolar type
II cell dysfunction in ARDS since the levels reflect the severity of
lung injury and neutrophilic inflammation. KL-6 release across
the alveolar epithelial barrier is associated with a poor
prognosis. The pathophysiological roles of KL-6 in the
development of ARDS warrant further study.
Introduction
Acute respiratory distress syndrome (ARDS) is characterized
by disruption of the alveolar–capillary barrier and by neu-
trophilic inflammation [1,2]. The pathology of ARDS consists
of inflammation in the alveolar space, with a predominance of
neutrophils. Analysis of bronchoalveolar lavage fluid (BALF)
from patients with ARDS has shown increased numbers of
activated neutrophils in the early stages of ARDS [3]. The
number of neutrophils in BALF relates to the severity of lung
ALI = acute lung injury; ARDS = acute respiratory distress syndrome; BALF = bronchoalveolar lavage fluid; CI = confidence interval; ELISA = enzyme-
linked immunosorbent assay; ENA-78 = epithelial-cell-derived neutrophil attractant 78; IL = interleukin; KL-6 = Kerbs von Lungren 6 antigen; VEGF 
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injury [4], and the persistence of neutrophils is associated with
increased mortality [5].
Kerbs von Lungren 6 antigen (KL-6) is a high-molecular-weight
glycoprotein, classified as cluster 9 (MUC1) of lung tumour
and differentiation antigens according to the findings of immu-
nohistochemical and flow cytometry studies [6]. KL-6 splits off
at the S–S bond near the epithelial membrane surface and
becomes distributed in pulmonary epithelial lining fluid. This
glycoprotein is predominantly expressed on alveolar type II
cells in the lung, with expression increasing in proliferating,
regenerating or injured type II cells more than normal type II
cells [7-9].
Serum levels of KL-6 are elevated in a variety of interstitial lung
diseases that are characterized by alveolar epithelial cell dam-
age. Serum KL-6 concentrations are associated with alveolar–
epithelial barrier dysfunction as they have been shown to cor-
relate with indices of alveolar–capillary permeability [10].
Two studies have examined the serum and oedema fluid KL-6
concentrations in adult patients with acute lung injury (ALI);
both studies found elevated plasma levels [8,11]. The study by
Ishizaka and colleagues demonstrated elevated levels of KL-6
in oedema fluid collected by bronchoscopic microsampling of
patients with ARDS, and confirmed primary human epithelial
cell production of KL-6 in response to proinflammatory
cytokines [8]. Both studies suggest that measuring KL-6 could
be a valuable marker of poor prognosis in clinical ALI, although
several questions regarding the relevance of elevated KL-6 in
ALI remain. Are KL-6 concentrations in BALF prognostic in
ALI? Does the degree of alveolar inflammation correlate with
levels of KL-6 within the lung? Does active alveolar infection
influence the KL-6 levels in ARDS? Can KL-6 be used to strat-
ify risk for ARDS in patient groups or individuals?
The present study demonstrates for the first time that the
BALF KL-6 concentration is elevated in patients with ARDS.
BALF KL-6 correlated with plasma KL-6 levels and was related
to the severity of neutrophilic inflammation. Alveolar infection
does not seem to determine the levels of KL-6 in either BALF
or plasma. We suggest that KL-6 may represent a useful
marker of alveolar type II cell dysfunction in ARDS since the
levels reflect the severity of lung injury and neutrophilic inflam-
mation but not the presence of alveolar infection.
Materials and methods
Participants
Consecutive patients with ARDS were studied within 48 hours
of admission to the critical care unit of University Hospital Bir-
mingham (Birmingham, UK) between 2004 and 2006. The
nature of illness precluded obtaining prospective consent in
those with ARDS; in this group, whenever possible, retrospec-
tive written informed consent was obtained. All other study
participants gave written informed consent. The study was
approved by the local research ethics committee.
Thirty patients were identified during the study as having ALI
or ARDS according to the American–European consensus
statement [12]. Patients were ventilated using pressure-con-
trolled ventilation aiming for tidal volumes of 6 ml/kg. Bron-
choscopy and bronchoalveolar lavage (was performed in all
patients immediately following inclusion and, when possible, 4
days later (n = 15). Of the 15 patients in whom repeat bron-
choscopy could not be performed, eight died, three were extu-
bated, and four had contraindications to bronchoscopy.
The patients' demographic characteristics were recorded at
baseline. The Acute Physiology and Chronic Health Evaluation
II score, the Simplified Acute Physiology Score II and the pre-
dicted intensive care unit mortality were recorded as global
markers of disease severity. The Murray Lung Injury Score and
the Sequential Organ Failure Assessment score were
recorded daily.
Exclusion criteria were age <18 years, severe obstructive air-
ways disease, neutropenia (defined as neutrophil count <0.3
× 109 l), and/or known/suspected brain stem death.
Healthy volunteers (n = 10, mean age 49 years, nonsmoking,
free from respiratory disease) were defined as normal individ-
uals. Twelve ventilated patients with risk factors for ALI but
who had not developed ALI at the time of recruitment were
included as 'at-risk' intensive therapy unit control individuals
(see Table 1).
Bronchoscopy
The bronchoscope was wedged into to a subsegmental bron-
chus in the middle lobe and 150 ml of 0.9% saline was instilled
in three 50 ml aliquots [3]. The BALF was aspirated and
placed immediately on ice until processing. Fifteen millilitres of
blood was collected simultaneously into lithium heparin tubes
(Becton Dickinson, Birmingham, UK) and was stored on ice
until processing.
Sample processing
The BALF volume was measured and then filtered through a
single layer of surgical gauze to remove debris, and was cen-
trifuged at 500 × g  for 5 minutes. The supernatant was
removed and stored at -80°C until subsequent analysis.
Whole blood was spun at 500 × g for 10 minutes, and the
plasma was removed and stored at -80°C until analysis.
ELISA and myeloperoxidase assay measurements
KL-6 was measured by ELISA (Eisai Corporation, Tokyo,
Japan) according to the manufacturer's instructions in BALF
and in plasma. The intra-assay coefficient of variation was
5.1% and the inter-assay coefficient of variation was 8.9% in
both BALF and plasma. BALF IL-8, epithelial-cell-derived neu-Available online http://ccforum.com/content/12/1/R12
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trophil attractant 78 (ENA-78) and vascular endothelial growth
factor (VEGF) were measured by ELISA (R&D Systems,
Abingdon, UK) according to the manufacturer's instructions.
Myeloperoxidase activity was measured by chromogenic sub-
strate assay as previously described (expressed as units of
activity per millilitre) [13].
Bronchoalveolar lavage fluid microbiology culture
The BALF from patients with ARDS was quantitatively cul-
tured. A growth of a pathogen >104 colony-forming units/ml
was considered to represent significant active infection.
Statistical methods
The Ryan–Joiner normality test was used to test the distribu-
tion of the data. The plasma and BALF KL-6 data were not nor-
mally distributed, and therefore are presented as the median
with 95% confidence interval (CI) for the median difference.
Between-group comparisons were performed using the
Mann–Whitney U test, and multiple group comparisons using
the Kruskal–Wallis test. Correlations were made using Pear-
son's test on log-transformed data and are 'day 0' compari-
sons unless otherwise stated.
The study was considered hypothesis-generating; a power
calculation was therefore not performed. All statistics were
performed using Minitab 14. P < 0.05 was considered statis-
tically significant.
Results
KL-6 is elevated in the plasma of patients with ARDS and 
reflects outcome
The median plasma KL-6 level on day 0 (422 u/ml) was signif-
icantly increased compared with both normal control individu-
als (137.1, 95% CI median difference = 31 to 397, P = 0.022)
and individuals at risk of ARDS (median = 222 u/ml, 95% CI
median difference = 22.4 to 276.4, P = 0.014). Plasma levels
from ARDS patients increased significantly from day 1 (422 u/
ml) to day 4 (588.7 u/ml, 95% CI = 120 to 189, P = 0.01) (Fig-
ure 1).
Patients who died had significantly higher plasma KL-6 con-
centration than survivors at both day 0 (median died 738 u/ml
versus survived 310 u/ml, P = 0.041) and day 4 (median died
909.8 u/ml versus survived 414.5 u/ml, P = 0.043) (Figure 2).
The plasma KL-6 level correlated significantly with the Murray
Lung Injury Score (r = 0.68 P = 0.001) (see Figure 3) but not
with the systemic injury scores – Simplified Acute Physiology
Score II, Acute Physiology and Chronic Health Evaluation II or
Sequential Organ Failure Assessment score (data not shown).
Both central venous blood and arterial blood were measured
in 12 patients with ARDS to look for a transpulmonary gradient
in KL-6, but the values were similar (median arterial 314 u/ml
versus venous 312 u/ml, P = 0.6) (data not shown).
Table 1
Parameter ARDS patients Individuals at risk of ARDS P value
Number of patients 30 12 -
Male:female (n) 17:13 7:5 -
Mean age (years) 62 (3.5) 59 (4.5) 0.6
Lung Injury Score 2.7 (0.42) 1.2 (0.3) 0.001
PaO2:FiO2 ratio (kPa) 16.1 (7) 33.5 (12.1) 0.0001
Acute Physiology and Chronic Health Evaluation II score 28.9 (5.7) 21.7 (8.9) 0.139
Simplified Acute Physiology Score II 55.8 (16.62) 54.8 (12.8) 0.639
Sequential Organ Failure Assessment score 14.9 (3.3) 7.1 (4.3) 0.001
Figure 1
Kerbs von Lungren 6 antigen levels in plasma and in bronchoalveolar  lavage fluid Kerbs von Lungren 6 antigen levels in plasma and in bronchoalveolar 
lavage fluid. Plasma and bronchoalveolar lavage fluid (BALF) levels of 
Kerbs von Lungren 6 antigen (KL-6) are persistently elevated in acute 
respiratory distress syndrome (ARDS) patients compared with normal 
and at-risk individuals. Plasma levels measured by ELISA.Critical Care    Vol 12 No 1    Nathani et al.
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BALF KL-6 level is elevated in patients with ARDS and 
reflects outcome
BALF KL-6 was detectable in all patients with ARDS (day 0
ARDS median BAL KL-6 concentration, 305 u/ml), and was
higher than both control individuals (median = 67 u/ml, 95%
CI median difference = 125 to 424, P = 0.002) and at-risk
individuals (median = 169.4, 95% CI median difference = 35
to 380, P = 0.008). KL-6 remained elevated at day 4 (median
= 401 u/ml) compared with both control individuals (median =
67 u/ml, 95% CI median difference = 125.7 to 424.9, P =
0.0008) and at-risk individuals (median = 169.4 u/ml, 95% CI
median difference = 59.3 to 725.6, P = 0.016) (Figure 1).
Plasma and BALF KL-6 levels on day 0 correlated in patients
with ARDS (r = 0.3260, P = 0.04) (data not shown).
BAL KL-6 did not correlate either with the Lung Injury Score,
the Simplified Acute Physiology Score II, or the Acute Physiol-
ogy and Chronic Health Evaluation II score. The BALF levels of
KL-6 were significantly higher in those that died compared
with those who survived, both on day 0 (median survived 308
u/ml versus died 608 u/ml, P = 0.046) and on day 4 (median
died 1,179 u/ml versus survived 360 u/ml, P = 0.036) (Figure
2).
BALF KL-6 correlates with cellular inflammation and 
BALF chemokines and the type II epithelial cell product 
VEGF
The BALF KL-6 concentration correlated with the BAL cell
count per millilitre (r = 0.318, P = 0.038) and with the BAL
myeloperoxidase activity (r = 0.363, P = 0.027) in patients
with ARDS (Figure 4a,b).
In addition, we evaluated the relationship between BALF KL-6
and BALF chemokine levels (IL-8 and ENA-78), which are
known to be elevated in ARDS. There was no correlation
between KL-6 and IL-8, but the log BALF KL-6 concentration
on day 0 did correlate significantly with ENA-78 (r = 0.37, P =
0.016). In addition, there was a significant relationship
between log BALF KL-6 and VEGF (r = 0.35, P = 0.024) (Fig-
ure 5a,b).
BALF KL-6 is not influenced by the presence of active 
infection in ARDS patients or the mode of lung injury
Previous studies have indicated that the mode of lung injury
can influence the inflammatory milieu and pulmonary mechan-
ics of the lung in ARDS [14]. To address this indication we
analysed the BALF KL-6 level by mode of lung injury and in
relation to whether BALF grew significant numbers of patho-
genic organisms. The mode of injury (direct versus indirect)
was defined clinically according to the presumed aetiology of
lung injury.
The presence of active alveolar infection was defined by the
presence of >104 colony-forming units of pathogenic bacteria
in BALF (irrespective of mode of injury). A significant growth of
pathogenic bacteria was observed in 10/32 patients on day 0.
The median KL-6 concentration in those with infection was
385 u/ml, compared with 314 u/ml in those with nonsignificant
growth or no growth (P = 0.37) (Figure 6). Where repeat bron-
choscopy was performed, none of the patients who grew path-
ogenic bacteria on the first lavage repeatedly grew the same
isolate. The BALF KL-6 level was 298 u/ml in patients with
direct lung injury and was 329 u/ml in those with indirect lung
injury (P = 0.48) (data not shown).
Discussion
In the present study we have extended previous observations
about KL-6 in both the plasma and the BALF from patients
with ARDS compared with normal individuals and at-risk indi-
viduals. Previous studies in adults with ALI used a broncho-
Figure 2
Kerbs von Lungren 6 antigen levels in survivors and nonsurvivors Kerbs von Lungren 6 antigen levels in survivors and nonsurvivors. 
Plasma and bronchoalveolar lavage fluid (BALF) Kerbs von Lungren 6 
antigen (KL-6) levels are increased in acute respiratory distress syn-
drome (ARDS) patients who subsequently die of the disease.
Figure 3
Correlation between Kerbs von Lungren 6 antigen and the Murray Lung  Injury Score Correlation between Kerbs von Lungren 6 antigen and the Murray Lung 
Injury Score. Log plasma levels of Kerbs von Lungren 6 antigen (KL-6) 
correlate with the Murray Lung Injury Score (LIS) (r = 0.68, P = 0.001).Available online http://ccforum.com/content/12/1/R12
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scopic microsampling probe for estimating the epithelial lining
oedema fluid KL-6 concentrations. Bronchoalveolar lavage
represents the better validated technique and allows both
sequential assessments and comparison with both normal
individuals and at-risk individuals. In our patients the levels of
KL-6 in the plasma reflected the severity of lung injury and
were highest in those that subsequently died. The fact that KL-
6 was not elevated in the plasma of an at-risk group of patients
who were ventilated suggests that increased plasma levels of
KL-6 reflect the pathophysiology of lung injury rather than rep-
resenting a nonspecific effect of mechanical ventilation or crit-
ical illness.
There is considerable speculation about the mechanism
whereby the KL-6 concentration is elevated in the plasma of
patients with ARDS. Until recently the primary cellular source
of KL-6 was thought to be type II pneumocytes [7] and the
concentration of KL-6 was estimated to be extremely high in
epithelial lining fluid [8,9]. It has been suggested that an
increase in circulating KL-6 levels in interstitial pneumonitis is
therefore due to an increase in KL-6 production by regenerat-
ing alveolar type II pneumocytes and/or to an enhanced per-
meability following destruction of the air–blood barrier in the
affected lungs [15]. Recent data suggest that the KL-6 levels
may indicate interstitial lung disease in patients since KL-6 is
a potent proproliferative and antiapoptotic agent upon lung
fibroblasts. Interestingly the effects of KL-6 were comparable
in magnitude with those of transforming growth factor beta,
basic fibroblast growth factor and platelet-derived growth fac-
tor, supporting the intriguing possibility that KL-6 may be a
Figure 4
Kerbs von Lungren 6 antigen correlation with bronchoalveolar lavage fluid cell count and myeloperoxidase activity Kerbs von Lungren 6 antigen correlation with bronchoalveolar lavage fluid cell count and myeloperoxidase activity. Bronchoalveolar lavage fluid 
(BALF) Kerbs von Lungren 6 antigen (KL-6) levels correlate with (a) the BALF cell count per millilitre (r = 0.318, P = 0.038) and (b) the BALF mye-
loperoxidase activity (r = 0.363, P = 0.027) in patients with acute respiratory distress syndrome.
Figure 5
Correlation of Kerbs von Lungren 6 antigen with bronchoalveolar lavage fluid chemokine levels Correlation of Kerbs von Lungren 6 antigen with bronchoalveolar lavage fluid chemokine levels. Bronchoalveolar lavage fluid (BALF) Kerbs von Lun-
gren 6 antigen (KL-6) correlates with (a) BALF epithelial-cell-derived neutrophil attractant 78 (ENA-78) (r = 0.37, P = 0.016) and (b) BALF vascular 
endothelial growth factor (VEGF) (r = 0.35, P = 0.024).Critical Care    Vol 12 No 1    Nathani et al.
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driver of fibroproliferation seen in ARDS patients. Whether KL-
6 in the plasma predicts the development of persistent fibro-
proliferative ARDS is worthy of further study.
Plasma levels of KL-6 have been previously shown to correlate
with indices of alveolar–capillary permeability, suggesting a
link between serum KL-6 and alveolar epithelial barrier dys-
function. Circulating levels of KL-6 have been used as both a
diagnostic tool and a prognostic tool in a variety of interstitial
pneumonitis, sarcoidosis and alveolar proteinosis. Two previ-
ous studies of KL-6 in plasma of ARDS patients have been
published. In the first, plasma levels of KL-6 correlated with the
oxygenation index and were significantly elevated by day 4. In
the more recent study in children with ARDS, there was a rela-
tionship between KL-6 and both the oxygenation index and
survival. Neither of these studies looked contemporaneously at
the alveolar compartment. A further study used bronchoscopic
micro-sample probe to sample oedema fluid early in the
course of ARDS [16]. In that study, plasma and epithelial lining
fluid levels were elevated in nonsurvivors and alveolar epithe-
lial type II cell production of KL-6 was shown to be cytokine
responsive. For this reason we assessed whether there was a
relationship between inflammation and lung levels of KL-6.
As might have been expected, the BALF levels of KL-6 were
significantly higher than those of either normal individuals or at-
risk control individuals. The BALF levels were significantly
higher in ARDS patients than the contemporaneous plasma
levels. Our data support the interpretation that the plasma KL-
6 level reflects the lung level as they correlate together,
although we did not demonstrate a significant transpulmonary
gradient. Within the lung the BALF levels did not reflect the
severity of lung injury or the presence of infection per se. The
BALF levels did both reflect outcome and correlated with the
degree of cellular inflammation/neutrophilic activation (mye-
loperoxidase) and chemokine levels (ENA-78). There was also
a significant relationship between BALF VEGF and BALF KL-
6. Since in situ hybridization studies have demonstrated that
alveolar type II cells are the predominant source of VEGF
within the lung, this correlation supports type II epithelial cells
as the main (but not necessarily sole) cellular source of KL-6
within the lung in ARDS. Nevertheless since neutrophilic
inflammation is an important determinant of alveolar capillary
damage, the relationship with alveolar inflammation suggests
that BALF KL-6 cannot simply be regarded as a marker of
regenerating epithelial cells.
The present study has several limitations. Firstly, our sequen-
tial assessment of KL-6 by bronchoscopy was only possible in
one-half of the patients due to early death, clinical improve-
ment or contraindications to bronchoscopy. This level of drop-
out, however, is in keeping with other published
bronchoscopic studies in ARDS [3,17]. Secondly, although
the lung is considered the predominant source of KL-6, recent
research has suggested other sites of production [18]. There-
fore, although we found that plasma and BALF levels corre-
lated with each other, we cannot be entirely sure of the cellular
source of plasma KL-6. This uncertainty could potentially be
important as it may limit the potential utility of plasma KL-6 as
a marker of lung epithelial damage in ARDS.
Conclusion
The present study demonstrated for the first time that the
BALF KL-6 concentration is elevated in patients with ARDS
but is not elevated in critically ill patients at risk of the disease.
BALF KL-6 correlated with plasma KL-6 and was related to the
severity of inflammation. Alveolar infection does not seem to
determine the levels of KL-6 in either BALF or plasma. These
observations support a role of proliferating, stimulated and or
injured pulmonary epithelial cells in the pathogenesis of ALI.
KL-6 may represent a useful marker of alveolar type II cell dys-
function in ARDS since levels reflect the severity of lung injury
and neutrophilic inflammation. These data also suggest that
KL-6 release across the alveolar epithelial barrier is associated
with a poor prognosis. The pathophysiological roles of KL-6 in
the development of ARDS warrant further study.
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